We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

97 hedge funds and large institutions have $241M invested in Cue Biopharma in 2020 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 40 increasing their positions, 22 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 7

82% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 22

5% more funds holding

Funds holding: 92 → 97 (+5)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.08% less ownership

Funds ownership: 2.21% → 2.13% (-0.08%)

17% less capital invested

Capital invested by funds: $291M → $241M (-$49.8M)

87% less call options, than puts

Call options by funds: $359K | Put options by funds: $2.72M

Holders
97
Holders Change
+5
Holders Change %
+5.43%
% of All Funds
1.72%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
13
Increased
40
Reduced
22
Closed
7
Calls
$359K
Puts
$2.72M
Net Calls
-$2.36M
Net Calls Change
-$2.55M

Top Buyers

Rank Fund Capital Flow
1
CA
Corriente Advisors
Texas
+$6.36M
2
Morgan Stanley
Morgan Stanley
New York
+$4.04M
3
PM
Prosight Management
Texas
+$2.62M
4
Millennium Management
Millennium Management
New York
+$2.42M
5
Goldman Sachs
Goldman Sachs
New York
+$2.34M

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$18.9M
2
WP
Woodline Partners
California
-$5.39M
3
Citadel Advisors
Citadel Advisors
Florida
-$2.53M
4
Federated Hermes
Federated Hermes
Pennsylvania
-$1.29M
5
BL
Bleichroeder LP
New York
-$999K
Name Holding Trade Value Shares
Change 		Change in
Stake
NCM
1
Nantahala Capital Management
Connecticut
$31.4M +$2.19M +5,485 +7%
BlackRock
2
BlackRock
New York
$27.1M +$630K +1,577 +2%
CA
3
Corriente Advisors
Texas
$24M +$6.36M +15,926 +33%
SPC
4
Slate Path Capital
New York
$18.6M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$18.1M +$847K +2,120 +5%
State Street
6
State Street
Massachusetts
$17.4M +$510K +1,277 +3%
PM
7
Prosight Management
Texas
$11.3M +$2.62M +6,554 +28%
Morgan Stanley
8
Morgan Stanley
New York
$6.81M +$4.04M +10,099 +126%
Goldman Sachs
9
Goldman Sachs
New York
$6.42M +$2.34M +5,854 +52%
WP
10
Woodline Partners
California
$6.38M -$5.39M -13,486 -44%
RSWM
11
Robertson Stephens Wealth Management
California
$6.05M – – –
ACA
12
Avoro Capital Advisors
New York
$5.66M -$18.9M -47,250 -76%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$5.39M +$520K +1,301 +10%
Millennium Management
14
Millennium Management
New York
$4.54M +$2.42M +6,068 +101%
Two Sigma Advisers
15
Two Sigma Advisers
New York
$4.39M +$763K +1,910 +20%
Northern Trust
16
Northern Trust
Illinois
$4.3M -$50.3K -126 -1%
Two Sigma Investments
17
Two Sigma Investments
New York
$4.07M +$335K +839 +8%
6CM
18
683 Capital Management
New York
$4M – – –
VC
19
Voss Capital
Texas
$2.76M -$77.9K -195 -3%
SMH
20
Sanders Morris Harris
Texas
$2.45M +$681K +1,705 +36%
Charles Schwab
21
Charles Schwab
California
$2.31M -$82.7K -207 -3%
PM
22
Precept Management
Texas
$1.88M – – –
N
23
Nuveen
North Carolina
$1.78M +$12K +30 +0.6%
PAWC
24
P.A.W. Capital
Connecticut
$1.75M +$1.86M +4,667 New
Bank of New York Mellon
25
Bank of New York Mellon
New York
$1.44M +$48.3K +121 +3%
1
2 3 4 5

CUE Hedge Fund Activity: Q4 2020 in Review

97 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q4 2020, worth a combined $241M — down 17% from $291M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new CUE positions and 7 closed out — a net gain of 6 holders — while 40 added to existing stakes and 22 trimmed.

The largest buyer was Corriente Advisors, adding an estimated $6.36M. The largest seller was Avoro Capital Advisors, cutting an estimated $18.9M.

  • 97 institutional investors held Cue Biopharma (CUE) as of Q4 2020, up from 92 in Q3 2020.
  • Funds reported $241M of Cue Biopharma stock for Q4 2020, down 17% quarter-over-quarter.
  • 13 funds opened new Cue Biopharma positions in Q4 2020 and 7 closed out, a net change of +6 holders.
  • The largest Cue Biopharma buyer in Q4 2020 was Corriente Advisors, an estimated $6.36M added.
  • The largest Cue Biopharma seller in Q4 2020 was Avoro Capital Advisors, an estimated $18.9M sold.

Based on aggregated 13F filings for Q4 2020.